Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Phase: N/A
Status: Recruiting
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Igor Koren, MD, MSc, Principal Investigator, Affiliation: Radix - medicinske storitve, Igor Koren s.p.
Overall contact:
AztraZeneca Slovenia Clinical Study Information, Phone: +38631318222, Email: gabrijela.dolenc@astrazeneca.com
Summary
We want to evaluate efficacy of Symbicort® Turbuhaler® (formoterol/budesonide) therapy for
asthma in real life conditions. For this purpose we will include both patients that are
treated with Symbicort® Turbuhaler® the "classical" maintenance only treatment approach as
well as those treated with the SMART approach.
Clinical Details
Official title: Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice
Study design: Case Control, Prospective
Primary outcome: to determine the efficacy of both possible treatment approaches with Symbicort® Turbuhaler®, measured by asthma control
Secondary outcome: to determine the number of maintenance and reliever inhalations of Symbicort® Turbuhaler®, as well as the concomitant usage of a separate reliever inhaler even in the case of SMART treatment approach
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients diagnosed with persistent asthma treated with Symbicort® Turbuhaler® in line
with its label
- non-pregnant females
- existing maintenance only treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg, 160
μg/4,5 μg or 320 μg/9 μg for at least 1 month
- existing SMART treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg or 160 μg /4,5 μg
for at least 1 month
Exclusion Criteria:
- patients not being treated with Symbicort® Turbuhaler®
- patients treated with Symbicort® Turbuhaler® for COPD
Locations and Contacts
AztraZeneca Slovenia Clinical Study Information, Phone: +38631318222, Email: gabrijela.dolenc@astrazeneca.com
Research Site, Celje, Slovenia; Recruiting
Research Site, Domzale, Slovenia; Recruiting
Research Site, Dvorec Sela, Slovenia; Recruiting
Research Site, Grosuplje, Slovenia; Recruiting
Research Site, Idrija, Slovenia; Recruiting
Research Site, Izola, Slovenia; Recruiting
Research Site, Jesenice, Slovenia; Recruiting
Research Site, Kamnik-Duplica, Slovenia; Recruiting
Research Site, Kranj, Slovenia; Recruiting
Research Site, Litija, Slovenia; Recruiting
Research Site, Ljubljana, Slovenia; Recruiting
Research Site, Lucija, Slovenia; Recruiting
Research Site, Maribor, Slovenia; Recruiting
Research Site, Murska Sobota, Slovenia; Recruiting
Research Site, Novo mesto, Slovenia; Recruiting
Research Site, Ptuja, Slovenia; Recruiting
Research Site, Ravne na Koroskem, Slovenia; Recruiting
Research Site, Sezana, Slovenia; Recruiting
Research Site, Slovenj Gradec, Slovenia; Recruiting
Research Site, Slovenska Bistrica, Slovenia; Recruiting
Research Site, Topolsica, Slovenia; Recruiting
Research Site, Velenje, Slovenia; Recruiting
Research Site, Vrhnika, Slovenia; Recruiting
Research Site, Zagorje, Slovenia; Recruiting
Additional Information
Starting date: April 2008
Ending date: October 2008
Last updated: October 29, 2008
|
